Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.
Also called NCT05761444
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 137 participants
- Sponsor
- Registry
-
NCT05761444
-
- Other papers using this trial's data
- The role of early ezetimibe combination with atorvastatin in patients with atherosclerotic cardiovascular disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05761444. Randomized; no masking; primary purpose treatment. Start 2023-07-26 (actual); primary completion 2024-09-04 (actual). Results posted on 2025-09-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
- Acronym
- BETTER
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Atozet 10/40 mg or 10/80 mg
- Intervention (Drug)
- Lipitor 40 mg or 80 mg
- Lead sponsor
- Organon and Co
- Collaborator
- IQVIA Pty Ltd
Record details
- Record id
cardio:ct-nct05761444- Content hash
17d846d9453e4c7c556d56d1a521508091b9d1352a9e098db22052947a50305c